Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for BCG-unresponsive high-risk non-muscle invasive bladder cancer
NL-OMON46995Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Complete response and Disease-free survival. Started Oct 2016; status: recruiting.
02
Drugs
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON46995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46995.